Compounds > plerixafor
Page last updated: 2024-08-24

plerixafor and Carcinoma, Pancreatic Ductal

plerixafor has been researched along with Carcinoma, Pancreatic Ductal in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Barmpounakis, P; Basu, B; Bax, L; Biasci, D; Brais, R; Connell, CM; Fearon, DT; Gale, D; Gallagher, FA; Gao, Y; Godfrey, E; Gopinathan, A; Hudecova, I; Isherwood, C; Janowitz, T; Jodrell, DI; Johnson, TI; Magiera, L; Mir, F; Pawula, M; Popa, EC; Richards, FM; Rosenfeld, N; Smoragiewicz, M; Thaventhiran, JED; Wang, Z1
Hwang, RF; Logsdon, CD; Ma, Y; Ullrich, SE1
Caballero, OL; Chan, DS; Connell, CM; Deonarine, A; Fearon, DT; Feig, C; Janowitz, T; Jodrell, DI; Jones, JO; Kraman, M; Roberts, EW; Teichmann, SA; Tuveson, DA; Wells, RJ; Zhao, Q1

Other Studies

3 other study(ies) available for plerixafor and Carcinoma, Pancreatic Ductal

ArticleYear
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 11-17, Volume: 117, Issue:46

    Topics: Aged; Benzylamines; Carcinoma, Pancreatic Ductal; Chemokine CXCL12; Colorectal Neoplasms; Cyclams; Female; Heterocyclic Compounds; Humans; Immunity; Immunotherapy; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Receptors, CCR2; Receptors, CXCR3; Receptors, CXCR4; Receptors, CXCR5; Receptors, CXCR6; Receptors, Interleukin-8A; Signal Transduction; Tumor Microenvironment

2020
Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer.
    Cancer research, 2013, Jul-01, Volume: 73, Issue:13

    Topics: Animals; Antineoplastic Agents; Benzylamines; Carcinoma, Pancreatic Ductal; Cell Communication; Cell Degranulation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coculture Techniques; Culture Media, Conditioned; Cyclams; Epithelial Cells; Heterocyclic Compounds; Humans; Interleukin-13; Mast Cells; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, CXCR4; Stromal Cells; Tryptases; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays

2013
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Dec-10, Volume: 110, Issue:50

    Topics: Analysis of Variance; Animals; Base Sequence; Benzylamines; Carcinoma, Pancreatic Ductal; Chemokine CXCL12; Cyclams; Endopeptidases; Enzyme-Linked Immunospot Assay; Fibroblasts; Flow Cytometry; Fluorescent Antibody Technique; Gelatinases; Heterocyclic Compounds; Immunohistochemistry; Immunotherapy; Membrane Proteins; Mice; Molecular Sequence Data; Pancreatic Neoplasms; Sequence Analysis, RNA; Serine Endopeptidases; Tumor Escape

2013